Chongqing Zhifei Biological Products (300122.CH) - Could Zhifei Support Its Valuation?

218 Views26 Apr 2021 09:05
After its COVID-19 vaccine got approved in March, the investment logic is different. This article analyzed the key catalysts of Zhifei (agency business, COVID-19 vaccine) and thoughts on valuation.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
x